Venus Remedies Ltd Hits Upper Circuit with Nearly 10% Gain Amid Strong Buying Pressure

Strong Intraday Performance and Price Action

On 11 Mar 2026, Venus Remedies Ltd (Stock ID: 568580) recorded an intraday high of ₹861.7, marking a fresh peak for the stock. The closing last traded price (LTP) stood at ₹861.5, just shy of the high, reflecting sustained demand throughout the trading session. The stock’s price band was set at 10%, and it reached the maximum permissible daily gain of 9.97%, triggering an upper circuit freeze as per exchange regulations.

The stock traded within a wide intraday range of ₹82.65, with a low of ₹779.05, indicating significant volatility but predominantly upward momentum. This price action was supported by a total traded volume of 1.03 lakh shares, generating a turnover of ₹8.77 crore, underscoring healthy liquidity for a micro-cap stock with a market capitalisation of ₹1,124 crore.

Outperformance Against Sector and Market Benchmarks

Venus Remedies outpaced the Pharmaceuticals & Biotechnology sector’s 1-day return of 0.85% and the Sensex’s decline of 1.10% on the same day. This divergence highlights the stock’s relative strength amid a broader market pullback, signalling focused investor interest in the company’s prospects.

Moreover, the stock has been on a consistent upward trajectory, gaining for six consecutive trading days and delivering a cumulative return of 32.04% during this period. This sustained rally reflects growing confidence in the company’s fundamentals and market positioning.

Technical Indicators and Moving Averages

Venus Remedies is trading comfortably above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical alignment suggests a robust uptrend and positive momentum, which often attracts further buying interest from technical traders and institutional investors alike.

The stock’s Mojo Score currently stands at 70.0, with a Mojo Grade of Buy, reflecting a favourable combination of fundamental and technical factors. Notably, this represents a slight downgrade from a previous Strong Buy rating assigned on 1 Feb 2026, indicating a more measured but still optimistic outlook from MarketsMOJO’s analytical framework.

Rising Investor Participation and Delivery Volumes

Investor interest in Venus Remedies has surged notably, with delivery volumes on 10 Mar 2026 reaching 36,210 shares. This figure represents a 228.56% increase compared to the five-day average delivery volume, signalling strong conviction among buyers who are holding shares rather than engaging in intraday trading.

Such rising delivery volumes often precede sustained price appreciation, as they indicate genuine accumulation rather than speculative activity. The stock’s liquidity profile supports trades of up to ₹0.06 crore based on 2% of the five-day average traded value, making it accessible for retail and institutional participants alike.

Regulatory Freeze and Unfilled Demand

With the stock hitting the upper circuit limit, trading was halted temporarily as per regulatory norms to curb excessive volatility. This freeze reflects the maximum allowable price movement of 10% for the day, which Venus Remedies nearly reached with a 9.97% gain.

The upper circuit freeze often indicates unfilled demand, where buy orders exceed sell orders at the capped price, preventing further upward movement during the session. This scenario underscores the strong bullish sentiment prevailing among market participants and suggests potential for continued momentum once trading resumes.

Company and Sector Context

Venus Remedies operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation, regulatory scrutiny, and evolving market dynamics. The company’s micro-cap status with a market capitalisation of ₹1,124 crore positions it as a nimble player capable of capitalising on niche opportunities.

Its recent price performance and technical strength may reflect positive developments in product pipelines, regulatory approvals, or strategic partnerships, although specific corporate announcements were not disclosed on the day of the rally.

Investor Takeaway and Outlook

Venus Remedies Ltd’s upper circuit hit on 11 Mar 2026 is a clear signal of strong market enthusiasm and robust buying interest. The stock’s outperformance relative to its sector and the broader Sensex, combined with rising delivery volumes and technical strength, suggests a positive near-term outlook.

However, investors should remain mindful of the micro-cap nature of the stock, which can entail higher volatility and liquidity risks. The recent downgrade from Strong Buy to Buy by MarketsMOJO on 1 Feb 2026 indicates a tempered but still favourable view, recommending a balanced approach to participation.

Given the unfilled demand and regulatory freeze, the stock may continue to exhibit momentum in subsequent sessions, provided broader market conditions remain supportive and company fundamentals sustain their positive trajectory.

Summary of Key Metrics:

• Market Capitalisation: ₹1,124 crore (Micro Cap)
• Day’s Price Change: ₹78.1 (9.97%)
• Intraday High: ₹861.7 (New 52-week & All-time High)
• Total Traded Volume: 1.03 lakh shares
• Turnover: ₹8.77 crore
• Consecutive Gains: 6 days, 32.04% cumulative return
• Mojo Score: 70.0 (Buy Grade, downgraded from Strong Buy)
• Sector Outperformance: +8.9% vs Pharmaceuticals & Biotechnology sector

Investors tracking Venus Remedies Ltd should monitor upcoming corporate developments and broader sector trends to gauge sustainability of this rally. The current momentum, supported by strong technicals and rising investor participation, positions the stock as a compelling candidate for those seeking exposure to the pharmaceuticals and biotechnology space within the micro-cap segment.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →